IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6

Journal of Medical Virology

Volumn 86, Issue 9, 2014, Pages 1482-1490

  Akkarathamrongsin, Srunthron ^a   Thong, Vo Duy ^a   Payungporn, Sunchai ^a   Poovorawan, Kittiyod ^a   Prapunwattana, Phisit ^a   Poovorawan, Yong ^a   Tangkijvanich, Pisit ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Interferon lambda 3; Interferon lambda 4; Interleukin 28B; Single nucleotide polymorphisms; Sustained virological response

Indexed keywords

DNA; INTERFERON; INTERFERON LAMBDA 4; INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; ALPHA INTERFERON; ANTIVIRUS AGENT; IFNL4 PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; DNA EXTRACTION; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; GENETIC ASSOCIATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; THAILAND;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RIBAVIRIN; THAILAND; TREATMENT OUTCOME;

EID: 84903954168     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23957     Document Type: Article

References (33)

1. Akkarathamrongsin S, Praianantathavorn K, Hacharoen N, Theamboonlers A, Tangkijvanich P, Tanaka Y, Mizokami M, Poovorawan Y. 2010a. Geographic distribution of hepatitis C virus genotype 6 subtypes in Thailand. J Med Virol 82:257-262.
2. Akkarathamrongsin S, Sugiyama M, Matsuura K, Kurbanov F, Poovorawan Y, Tanaka Y, Mizokami M. 2010b. High sensitivity assay using serum sample for IL28B genotyping to predict treatment response in chronic hepatitis C patients. Hepatol Res 40:956-962.
3. Antaki N, Bibert S, Kebbewar K, Asaad F, Baroudi O, Alideeb S, Hadad M, Abboud D, Sabah H, Bochud PY, Negro F. 2012. IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5. Gut 61:1640-1641.
4. Argentini C, Genovese D, Dettori S, Rapicetta M. 2009. HCV genetic variability: From quasispecies evolution to genotype classification. Future Microbiol 4:359-373.
5. Bedossa P, Poynard T. 1996. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289-293.
6. Chao DT, Abe K, Nguyen MH. 2011. Systematic review: Epidemiology of hepatitis C genotype 6 and its management. Aliment Pharmacol Ther 34:286-296.
7. De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, Soffredini R, De Francesco R, Prati GM, D'Ambrosio R, Cheroni C, Donato MF, Colombo M. 2012. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 55:336-342.
8. Fishman SL, Branch AD. 2009. The quasispecies nature and biological implications of the hepatitis C virus. Infect Genet Evol 9:1158-1167.
9. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401.
10. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, Morris MD, Hajarizadeh B, Amin J, Cox AL, Kim AY, McGovern BH, Schinkel J, George J, Shoukry NH, Lauer GM, Maher L, Lloyd AR, Hellard M, Dore GJ, Prins M, InC3 Study Group. 2014. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 59:109-120.
11. Hayes CN, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Imamura M, Ochi H, Kamatani N, Nakamura Y, Chayama K. 2011. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 60:261-267.
12. Jia Z, Ding Y, Tian S, Niu J, Jiang J. 2012. Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: Results from a meta-analysis. PLoS ONE 7:e45698.
13. Lavanchy D. 2009. The global burden of hepatitis C. Liver Int 29:74-81.
14. Liang TJ, Ghany MG. 2013. Current and future therapies for hepatitis C virus infection. N Engl J Med 368:1907-1917.
15. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG. 2010. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 139:821-827.
16. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, Tillmann HL, Muir AJ, McHutchison JG. 2010. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 138:2307-2314.
17. Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjoro K, Dalgard O. 2011. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 53:746-754.
18. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, Romero-Gomez M, Barroso N, Aguilar-Reina J, Nunez-Roldan A, Gonzalez-Escribano MF. 2010. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 52:33-37.
19. Nguyen LH, Nguyen MH. 2013. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther 37:921-936.
20. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR. 2013. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45:164-171.
21. Rangnekar AS, Fontana RJ. 2013. IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: A meta-analysis. J Viral Hepat 20:377-384.
22. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Gunthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY. 2010. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study. Gastroenterology 138:1338-1345.
23. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, Herrmann E, Lotsch J, Berg T. 2011. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 54:415-421.
24. Scherzer TM, Hofer H, Staettermayer AF, Rutter K, Beinhardt S, Steindl-Munda P, Kerschner H, Kessler HH, Ferenci P. 2011a. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol 54:866-871.
25. Scherzer TM, Stattermayer AF, Strasser M, Laferl H, Maieron A, Stauber R, Datz C, Dulic-Lakovic E, Steindl-Munda P, Hofer H, Ferenci P. 2011b. Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin. Hepatology 54:1518-1526.
26. Seto WK, Tsang OT, Liu K, Chan JM, Wong DK, Fung J, Lai CL, Yuen MF. 2013. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. J Viral Hepat 20:470-477.
27. Stattermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, Zinober K, Datz C, Maieron A, Dulic-Lakovic E, Kessler HH, Steindl-Munda P, Strasser M, Krall C, Ferenci P. 2011. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol 9:344-350.
28. Sunanchaikarn S, Theamboonlers A, Chongsrisawat V, Yoocharoen P, Tharmaphornpilas P, Warinsathien P, Sinlaparatsamee S, Paupunwatana S, Chaiear K, Khwanjaipanich S, Poovorawan Y. 2007. Seroepidemiology and genotypes of hepatitis C virus in Thailand. Asian Pac J Allergy Immunol 25:175-182.
29. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100-1104.
30. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109.
31. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798-801.
32. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. 2010. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139:120-129.
33. Zhang XH, Cai QX, Hong CX, Lin CS, Zhao ZX. 2013. Prevalence of IL-28B and ITPA genotypes in Chinese Han population infected persistently with hepatitis C virus genotype 6 or HCV-1. J Med Virol 85:1163-1169.